PPARγ: the dominant regulator among PPARs in dry eye lacrimal gland and diabetic lacrimal gland.
PPARγ
diabetes
dry eye
lacrimal gland
rat
Journal
International journal of ophthalmology
ISSN: 2222-3959
Titre abrégé: Int J Ophthalmol
Pays: China
ID NLM: 101553860
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
11
2019
accepted:
10
04
2020
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
23
6
2020
Statut:
epublish
Résumé
To investigate the regulatory roles of the members of the peroxisome proliferator-activated receptor (PPAR) family in lacrimal gland dysfunction under conditions of desiccating stress or diabetes. Quantitative polymerase chain reaction (qPCR) was used to examine the expression of PPARs in the cornea, conjunctiva, meibomian gland, and lacrimal gland in adult rats. The rats were divided into 3 groups: a control group, dry eye group, and diabetic group. The phenol red threads test, tear film break-up time (BUT) test and fluorescein staining were carried out to evaluate the development of dry eye. Based on bioinformatics research, qPCR was used to examine the expression level of PPARγ, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), sirtuin 1 (Sirt1), myeloid differentiation factor 88 (MyD88) and transforming growth factor-β (TGF-β) in the lacrimal glands. PPARα and PPARβ/δ were mainly expressed in the conjunctiva and the lacrimal gland, respectively. However, PPARγ was expressed in both the conjunctiva and lacrimal gland, at much higher levels than those measured for PPARα and PPARβ/δ. Dry eye rats and diabetic rats both showed decreased tear secretion, shortened BUT, and increased corneal staining. Significant changes in gene expression were observed compared with the control group. In the lacrimal glands of dry eye rats and diabetic rats, expression of PPARγ decreased ( Among PPARs, PPARγ might play a dominant role in the regulation of metabolic- and inflammatory-signaling pathways on the ocular surfaces and in lacrimal glands. Down-regulation of PPARγ is highly relevant to lacrimal gland dysfunction under desiccating-stress and diabetic conditions. PPARγ, thus, is a potential therapeutic target in the treatment of environment- or diabetes-induced dry eye diseases.
Identifiants
pubmed: 32566495
doi: 10.18240/ijo.2020.06.02
pii: ijo-13-06-860
pmc: PMC7270247
doi:
Types de publication
Journal Article
Langues
eng
Pagination
860-869Informations de copyright
International Journal of Ophthalmology Press.
Références
J Ophthalmol. 2016;2016:8201053
pubmed: 27213053
Int J Mol Sci. 2018 Mar 20;19(3):
pubmed: 29558390
Ophthalmologe. 1994 Apr;91(2):235-9
pubmed: 8012143
J Adv Pharm Technol Res. 2011 Oct;2(4):236-40
pubmed: 22247890
N Engl J Med. 2018 Jun 07;378(23):2212-2223
pubmed: 29874529
Invest Ophthalmol Vis Sci. 2012 Aug 13;53(9):5443-50
pubmed: 22789923
Clin Interv Aging. 2018 Dec 27;14:53-63
pubmed: 30643394
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5888-95
pubmed: 26348638
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):963-7
pubmed: 11923235
Cytokine Growth Factor Rev. 2011 Jun;22(3):131-9
pubmed: 21757394
Curr Eye Res. 2010 Feb;35(2):165-75
pubmed: 20136427
J Ophthalmol. 2016;2016:7542929
pubmed: 27042343
Eur J Pharmacol. 2019 May 15;851:133-143
pubmed: 30797787
Ocul Surf. 2019 Oct;17(4):777-786
pubmed: 31201956
Neurosci Lett. 2017 Jun 9;651:128-133
pubmed: 28483651
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES102-DES108
pubmed: 30481813
Mol Med Rep. 2014 May;9(5):2015-23
pubmed: 24626526
Exp Eye Res. 2016 Feb;143:1-8
pubmed: 26463157
J Mol Endocrinol. 2018 May;60(4):R201-R212
pubmed: 29467141
Diabetes Res Clin Pract. 2017 Nov;133:124-130
pubmed: 28934669
J Ocul Pharmacol Ther. 2017 Jan/Feb;33(1):24-33
pubmed: 28009531
Cell Metab. 2007 Oct;6(4):307-19
pubmed: 17908559
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Diabetes Care. 2014 Oct;37(10):e210-1
pubmed: 25249675
Mol Metab. 2015 Mar 05;4(5):378-91
pubmed: 25973386
Immunology. 2008 Nov;125(3):344-58
pubmed: 18422969
Int J Mol Med. 2016 Oct;38(4):1003-11
pubmed: 27499172
Int J Clin Exp Pathol. 2015 Jun 01;8(6):7644-53
pubmed: 26261685
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES71-DES79
pubmed: 30481809
Dis Model Mech. 2018 Apr 26;11(4):
pubmed: 29549140
J Immunol Res. 2016;2016:8167273
pubmed: 26904696
Genome Biol. 2003;4(5):P3
pubmed: 12734009
Endocrine. 2009 Aug;36(1):161-8
pubmed: 19551521
Int J Mol Sci. 2018 Jun 01;19(6):
pubmed: 29865151
Molecules. 2019 Feb 20;24(4):
pubmed: 30791543
Am J Physiol Endocrinol Metab. 2010 Mar;298(3):E419-28
pubmed: 19996381
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES94-DES101
pubmed: 30481812
Toxicol Appl Pharmacol. 2016 Aug 15;305:93-102
pubmed: 27292124
Brain Res. 2010 Mar 31;1322:102-8
pubmed: 20132800
Biochem Biophys Res Commun. 2009 Aug 28;386(3):459-62
pubmed: 19527689
Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15401-6
pubmed: 24003152
PLoS One. 2016 Feb 01;11(2):e0147846
pubmed: 26828208
Cell Death Dis. 2014 Jun 26;5:e1309
pubmed: 24967971
PLoS One. 2015 Jan 15;10(1):e0115333
pubmed: 25590134
J Ethnopharmacol. 2018 Apr 6;215:91-100
pubmed: 29288830
J Ocul Pharmacol Ther. 2003 Dec;19(6):579-87
pubmed: 14733715
Acta Ophthalmol. 2014 Mar;92(2):e96-e104
pubmed: 23782539
BMC Ophthalmol. 2018 May 10;18(1):117
pubmed: 29747621
Arch Biochem Biophys. 2014 Feb 1;543:40-7
pubmed: 24374034
Blood. 2005 Dec 1;106(12):3888-94
pubmed: 16105976
Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5108-5115
pubmed: 30372737
Nucleic Acids Res. 2010 Nov;38(21):7458-71
pubmed: 20660480